Mark J. Vignola

Mark J. Vignola, listed as finance chief, appears in our data through filings on Terns Pharmaceuticals, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 31 May 2022 to 6 January 2025, the count stands at 10 filings.

Market trades split into 5 purchases (€46k) and 3 sales (€196k). The net balance comes to €150k on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 1 share grant and 1 option exercise. In 2025 alone, the filings show no purchases and 2 sales.

A typical purchase (the median) is worth €10k. On 5 out of 5 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

Most recently, on 6 January 2025, the filings show an open-market sale worth €51k in Terns Pharmaceuticals, Inc. The clock since the last published purchase (4 June 2024) now reads 872 days. The median gap between a trade and its publication by SEC (Form 4) is 3 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.